What does a post-pan­dem­ic IPO fil­ing look like? Hong Kong biotech ap­pli­ca­tion of­fers clues

As Covid-19 be­comes a per­ma­nent fix­ture on se­cu­ri­ties doc­u­ments, a new biotech IPO fil­ing in Hong Kong has of­fered a glimpse of what the out­look is like on the oth­er end of the tun­nel.

Oc­u­men­sion had just start­ed a Phase III tri­al for its lead drug, a cor­ti­cos­teroid-re­leas­ing in­trav­it­re­al im­plant in-li­censed from Eye­Point Phar­ma­ceu­ti­cals, when the first cas­es of a mys­te­ri­ous pneu­mo­nia were re­port­ed in Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER